Can we increase the effectiveness of anti-TNF therapy?
Martin Bortlík Orcid.org 1,2,3
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Jalali Y, Krajčovičová A, Hlavatý T. Therapeutic drug monitoring in treatment of inflammatory bowel disease with infliximab. Gastroent Hepatol 2018; 72 (1): 41–46. doi: 10.14735/amgh201841.
2. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59 (1): 49–54. doi: 10.1136/gut.2009.183095.
3. Papamichael K, Rivals-Lerebours O, Billiet T et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Crohns Colitis 2016; 10 (9): 1015–1023. doi: 10.1093/ecco-jcc/jjw067.
4. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (2): 330–335. doi: 10.1016/j.cgh.2014.07.041.
5. Bortlík M, Ďuricová D, Malíčková K et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohn Colitis 2013; 7 (9): 736–743. doi: 10.1016/j.crohns.2012.10.019.
6. Cornillie F, Hanauer SB, Diamond RH et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63 (11): 1721–1727. doi: 10.1136/ gutjnl-2012-304094.
7. Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148 (7): 1320–1329. doi: 10.1053/j.gastro.2015.02. 031.